

EVUSHELD CHECKLIST FOR MFA CLINIC STAFF

Tixagevimab plus cilgavimab (Evusheld), administered as intramuscular injections as SARS-CoV-2 pre-exposure prophylaxis (PrEP), can be ordered in Epic and administered as a pair of intramuscular injections in your designated clinical areas. Below are the recommended steps to follow.

PATIENT SELECTION AND ORDERING

- After a provider has identified a patient and offered Evusheld administration, the provider must place an order in Epic as a clinic administered medication.
 - If a patient has not received Evusheld yet, the default order will appear as the currently recommended 600 mg dose (tixagevimab 300 mg/3.0 mL and cilgavimab 300 mg/3.0 mL).
 - If a patient already received Evusheld but at the previously authorized 300 mg dose (tixagevimab 150 mg/1.5 mL and cilgavimab 150 mg/1.5 mL), the order should appear as a 300 mg dose (tixagevimab 150 mg/1.5 mL and cilgavimab 150 mg/1.5 mL).
- Your designated clinic/nurse manager must request the corresponding number of Evusheld packs via Cognito [here](#) (must use Google Chrome) and then pick up from the clinic pharmacy dispensary.
- At the time of pick up, clinic staff should provide the medical record number (MRN) of the patient(s) to receive administration to ensure equity and accountability in allocation.



ADMINISTRATION

- Patients can receive Evusheld during a scheduled clinic visit or as a walk-in injection visit.
- Provide a copy of the Evusheld [Fact Sheet](#) for Patients, Parents and Caregivers Emergency Use Authorization before injection. This is not an informed consent (does not need a signature).
- Each Evusheld pack contains two vials; one of each antibody. Each vial contains an overfill to allow the withdrawal of 150 mg (1.5 mL). The currently authorized 600 mg dose would require two vials of tixagevimab and two vials of cilgavimab (two Evusheld packs per patient).
- Administer the two components of Evusheld consecutively at different injection sites, and ensure that the administration sites are appropriate for the volume.
 - Currently authorized dose (3 mL per injection): the gluteal muscles are preferred.
 - Previously authorized dose (1.5 mL per injection): the deltoid or gluteal muscles can be used.
- Clinically monitor individuals after injections and observe for 1 hour.